MAPK pathway alterations as a targetable vulnerability in bladder cancer.

被引：0
|
作者：
D'Andrea, Vincent
Bekele, Raie
Hanlon, Timothy
Zhou, Yuzhen
Chroneos, Rea
Stelter, Isabella
Mouw, Kent William
机构：
[1] Brigham & Womens Hosp, Boston, MA USA
[2] Dana Farber Canc Inst, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期
关键词：
3282-3301-3439-2725; 261-265-9287; 281-318-9705-11350; 3282-206-4957-326-5009-5024-5026; 261-566-148; 6; 2; 166; 4344; 62; 3; 1; 38092-38288; 38092-30665; 38092-26655; 38092-28187; 38092-26692; 8; 4;
D O I：
10.1200/JCO.2024.42.4_suppl.672
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
672
引用
收藏
页码：672 / 672
页数：1
相关论文
共 50 条
  • [1] MAPK pathway alterations are a targetable vulnerability in bladder cancer
    Bekele, Raie
    Samant, Amruta
    Hanlon, Timothy
    Mouw, Kent
    CANCER RESEARCH, 2023, 83 (07)
  • [2] The genomic landscape of TERT alterations in bladder cancer.
    Jalkanen, Aimee
    Basu, Gargi D.
    Hall, David W.
    Hoag, Jess R.
    LoBello, Janine R.
    Baehner, Frederick L.
    Thakkar, Snehal Govind
    Dorff, Tanya B.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [3] DNA Repair Pathway Alterations in Bladder Cancer
    Mouw, Kent W.
    CANCERS, 2017, 9 (04)
  • [4] Alterations in the cell cycle checkpoint pathway in breast cancer.
    Basu, Gargi Dan
    White, Tracey
    LoBello, Janine R.
    Kurdoglu, Ahmet
    Krishnan, Subha
    Gonzalez, Laura
    Royce, Thomas
    Kiefer, Jeff
    Cherni, Irene
    Aldrich, Jessica
    Izatt, Tyler
    Russell, Megan
    Nasser, Sara
    Carpten, John D.
    Craig, David W.
    Demeure, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (28)
  • [5] Model for Prioritizing Targetable Alterations in Cancer
    Dienstmann, Rodrigo
    JCO PRECISION ONCOLOGY, 2018, 2 : 1 - 4
  • [6] YAP Triggers Bladder Cancer Proliferation by Affecting the MAPK Pathway
    Qiu, Dandan
    Zhu, Yan
    Cong, Zhicheng
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 12205 - 12214
  • [7] Molecular characterization of the Ras-MAPK pathway in metastatic breast cancer.
    Tiu-Lim, Justin Wayne Wong
    Xiu, Jun Yin Joanne
    Korn, Wolfgang Michael
    Lenz, Heinz-Josef
    In, Gino Kim
    Torres, Evanthia T. Roussos
    Lu, Janice M.
    Spicer, Darcy V.
    Xia, Bing
    Hoon, Dave S. B.
    Krill-Jackson, Elisa
    Heeke, Arielle Lutterman
    Sammons, Sarah
    Isaacs, Claudine
    Ademuyiwa, Foluso Olabisi
    Ma, Cynthia X.
    Tan, Antoinette R.
    Kang, Irene
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [8] Ras-MAPK Pathway as a Therapeutic Target in Cancer - Emphasis on Bladder Cancer
    Dangle, Pankaj P.
    Zaharieva, Boriana
    Jia, Hongtao
    Pohar, Kamal S.
    RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2009, 4 (02) : 125 - 136
  • [9] PTEN Association with mTOR Pathway Activation and Outcomes in Bladder Cancer.
    Orloff, M.
    Elson, P.
    Yang, Y.
    Eng, C.
    Hansel, D. E.
    MODERN PATHOLOGY, 2011, 24 : 396A - 396A
  • [10] Genomic alterations, proliferation, and prognosis in pT1 bladder cancer.
    Gorog, JP
    Suess, K
    Richter, J
    Jiang, F
    Moch, H
    Gasser, TC
    Mihatsch, MJ
    LABORATORY INVESTIGATION, 1997, 76 (01) : 438 - 438
12345